| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 33.122 | 119.550 | - | 207.013 | 243.625 | 245.852 | 223.456 | 246.355 | 281.108 | 363.930 |
| Total Income - EUR | 33.122 | 119.550 | - | 207.013 | 243.625 | 245.852 | 223.456 | 246.355 | 281.108 | 363.930 |
| Total Expenses - EUR | 22.603 | 104.887 | - | 187.219 | 227.233 | 237.923 | 211.688 | 226.170 | 256.824 | 335.579 |
| Gross Profit/Loss - EUR | 10.519 | 14.663 | - | 19.795 | 16.393 | 7.929 | 11.768 | 20.185 | 24.283 | 28.351 |
| Net Profit/Loss - EUR | 9.525 | 12.738 | - | 17.709 | 13.956 | 5.463 | 9.533 | 17.722 | 21.472 | 23.815 |
| Employees | 1 | 4 | - | 4 | 7 | 8 | 8 | 6 | 6 | 5 |
Check the financial reports for the company - Apoteka Irispharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.215 | 5.828 | - | 12.395 | 21.373 | 20.968 | 15.449 | 10.427 | 7.363 | 5.116 |
| Current Assets | 13.726 | 35.724 | - | 81.786 | 90.574 | 94.199 | 111.091 | 95.799 | 114.780 | 123.030 |
| Inventories | 6.647 | 19.613 | - | 21.975 | 67.435 | 43.027 | 44.053 | 45.420 | 60.613 | 68.382 |
| Receivables | 2.431 | 4.936 | - | 27.071 | 21.050 | 29.794 | 32.566 | 42.454 | 44.936 | 54.136 |
| Cash | 4.647 | 11.175 | - | 32.739 | 2.089 | 21.378 | 34.472 | 7.926 | 9.230 | 513 |
| Shareholders Funds | 9.052 | 21.698 | - | 54.895 | 67.998 | 72.173 | 80.105 | 48.517 | 69.719 | 82.288 |
| Social Capital | 45 | 45 | - | 43 | 253 | 248 | 243 | 243 | 243 | 241 |
| Debts | 5.888 | 19.855 | - | 39.286 | 43.949 | 42.994 | 46.435 | 57.709 | 52.424 | 45.858 |
| Income in Advance | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Apoteka Irispharm Srl